The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study

The present study investigated the clinical implications of pretreatment carbohydrate antigen 125 (CA-125) levels and CA-125 normalization in patients with ovarian clear cell carcinoma (CCC), and it provides useful information for the improvement of monitoring strategies for this lethal disease. The...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-03, Vol.7 (13), p.15566-15576
Main Authors: Bai, Huimin, Sha, Guisha, Xiao, Meizhu, Gao, Huiqiao, Cao, Dongyan, Yang, Jiaxin, Chen, Jie, Wang, Yue, Zhang, Zhenyu, Shen, Keng
Format: Article
Language:English
Subjects:
Adenocarcinoma, Clear Cell - blood
Adenocarcinoma, Clear Cell - drug therapy
Adenocarcinoma, Clear Cell - mortality
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - blood
CA-125 Antigen - blood
Carcinoma, Ovarian Epithelial
Female
Humans
Middle Aged
Neoplasms, Glandular and Epithelial - blood
Neoplasms, Glandular and Epithelial - drug therapy
Neoplasms, Glandular and Epithelial - mortality
Ovarian Neoplasms - blood
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - mortality
Prognosis
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study investigated the clinical implications of pretreatment carbohydrate antigen 125 (CA-125) levels and CA-125 normalization in patients with ovarian clear cell carcinoma (CCC), and it provides useful information for the improvement of monitoring strategies for this lethal disease. The medical records of patients with ovarian CCC who had undergone primary staging surgery or cytoreductive surgery followed by systemic chemotherapy were retrospectively reviewed. A range of clinico-pathological parameters were collected and examined. A total of 375 women were included in the analysis. FIGO stage (p < 0.001) was identified as the only significant prognostic factor for relapse. Residual tumor and advanced stage (p = 0.001 and p < 0.001, respectively) were identified as independent adverse factors for survival. The potential risk factors associated with elevated pretreatment CA-125 levels included advanced-stage disease, positive residual tumors and negative endometriosis (p < 0.001, p = 0.001 and p
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.7216